1
|
Lu Y, Deng Y, Liu W, Jiang M, Bai G. Searching for calcium antagonists for hypertension disease therapy from Moutan Cortex, using bioactivity integrated UHPLC-QTOF-MS. PHYTOCHEMICAL ANALYSIS : PCA 2019; 30:456-463. [PMID: 30859657 DOI: 10.1002/pca.2828] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 01/29/2019] [Accepted: 02/02/2019] [Indexed: 06/09/2023]
Abstract
INTRODUCTION Calcium channel blockers (CCBs) are currently the most commonly used drugs for the treatment of hypertension. Moutan Cortex (MC), a traditional Chinese herb, has been found to have an anti-hypertensive effect. However, its potential mechanisms in the regulation of intracellular calcium concentration ([Ca2+ ]i ) remain poorly understood. OBJECTIVE The main objective of this work was to identify the potential calcium antagonists from MC and study their molecular mechanisms. METHODS Ultra-high performance liquid chromatography-quadrupole-time-of-fight-mass spectrometry (UHPLC-QTOF-MS) analysis combined with a dual-luciferase reporter assay was utilised to systematically screen the calcium antagonistic active ingredients in the methanol extract of MC. Additionally, the molecular mechanism of these compounds was further studied using live-cell imaging analysis with the calcium ion (Ca2+ ) probe dye fluo-4/AM to monitor changes in [Ca2+ ]i . RESULTS Three monoterpenoids (paeoniflorin, benzoylpaeoniflorin and mudanpioside C), one phenolic acid (paeonol) and one gallotannin (1,2,3,4,6-O-pentagalloylglucose) were screened out as potential calcium antagonists in MC. Among them, the calcium antagonistic activity of benzoylpaeoniflorin, mudanpioside C and 1,2,3,4,6-O-pentagalloylglucose is first reported. Additionally, paeoniflorin, benzoylpaeoniflorin, mudanpioside C and paeonol can effectively block voltage-operated Ca2+ channels (VOCCs) to exert calcium antagonism, while 1,2,3,4,6-O-pentagalloylglucose plays a role in blocking inositol 1,4,5-trisphosphate receptors (IP3Rs). CONCLUSION This work indicated that the anti-hypertensive efficacy of MC acted through multiple components selectively antagonising multiple cell signalling pathways to regulate [Ca2+ ]i . Furthermore, they could be considered as a reference standard for controlling the quality of Chinese medicinal materials.
Collapse
Affiliation(s)
- Yujie Lu
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, P. R. China
| | - Yanfang Deng
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, P. R. China
| | - Wenjuan Liu
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, P. R. China
| | - Min Jiang
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, P. R. China
| | - Gang Bai
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, P. R. China
| |
Collapse
|
2
|
Zhang JQ, Yang GH, Zhou X, Liu JX, Shi R, Dong Y, Chen SB, Li YM. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. Medicine (Baltimore) 2019; 98:e14907. [PMID: 30896643 PMCID: PMC6708765 DOI: 10.1097/md.0000000000014907] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 12/18/2018] [Accepted: 02/22/2019] [Indexed: 01/14/2023] Open
Abstract
Evidence has shown that angiotensin II type 1 receptor antagonists have lower blood pressure and have target organ protective effects, but this is not the case for the drug allisartan isoproxil. The aim of this study was to evaluate the effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.In total, 80 essential hypertensive participants were randomly divided into an allisartan group and a nifedipine group (n = 40 per group), and their blood pressure was measured once per month for 6 months. A 2-dimensional echocardiogram was performed at baseline and at the end of the study. The serum levels of renal injury indexes, endothelial function markers, inflammatory factors, blood biochemical assays and urinary measurements were determined at baseline and at 6 months.At the end of the study, both systolic and diastolic blood pressure were significantly decreased in the allisartan group compared with baseline and showed the same antihypertensive effect as the nifedipine group. Meanwhile, the left ventricular remodeling, 24-hours levels of urinary microalbumin, endothelial dysfunction, and arterial stiffness were all significantly improved compared with that of the baseline and the nifedipine group (all P < .05).The present study showed that allisartan isoproxil had favorable blood pressure lowering and heart, renal, and endothelial protective effects in patients with mild to moderate essential hypertension.
Collapse
Affiliation(s)
- Jian-Qi Zhang
- Graduate School of Tianjin Medical University
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Pingjin Hospital Heart Center, Tianjin, China
| | | | - Xin Zhou
- Graduate School of Tianjin Medical University
| | | | - Rui Shi
- Graduate School of Tianjin Medical University
| | - Yan Dong
- Graduate School of Tianjin Medical University
| | | | - Yu-Ming Li
- Graduate School of Tianjin Medical University
| |
Collapse
|
3
|
Lin Y, Ma L. Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13152. [PMID: 30508892 PMCID: PMC6283187 DOI: 10.1097/md.0000000000013152] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Acute perioperative hypertension has been associated with poor outcomes of surgery, and the role of calcium channel blockers (CCB) on controlling perioperative blood pressure (BP) remains controversial. Thus, this meta-analysis was designed to assess the efficacy and safety of CCB in treating perioperative hypertension compared with other antihypertensive agents. METHODS PubMed, Medline, Cochrane, and EMABSE databases was systematically searched up to January 2018 for randomized control trials (RCTs) or other control studies comparing the efficacy of CCB versus other antihypertensive medicines for perioperative hypertension modulation. The efficacy and safety of CCB in treating perioperative hypertension were assessed through pooling mean difference (MD) with its 95% confidence interval (CI) or risk ratio (RR) with its 95% CI. RESULTS In total, 14 studies were included in the meta-analysis. There is no significant difference regarding successful treatment (RR = 2.64, 95% CI: 0.95, 7.29; I = 97%, P <.05), systolic blood pressure (SBP) (MD = -7.05, 95% CI: -16.27, 2.17; I = 78%, P <.05), overall adverse events (RR = 0.88, 95% CI: 0.66, 1.16; I = 54%, P = .02), atrial fibrillation (RR = 0.80, 95% CI: 0.60, 1.07; I = 32%, P = .20) and heart rates (MD = -1.05, 95% CI: -7.81, 5.71; I = 84%, P < .05) between patients treated by CCB and other drugs. In the subgroup analysis, statistical significance can be observed regarding successful treatment (RR = 3.46, 95%CI: 1.67, 7.18; I = 84%, P <.05) and postoperative SBP (MD = -9.98, 95%CI: -20.03, 0.08; I = 97%, P <.05) in the RCTs subgroup. CONCLUSION CCB was highly effective and well tolerated for treating perioperative hypertension.
Collapse
|
4
|
Zhang YT, Xiao MF, Liao Q, Liu WL, Deng KW, Zhou YQ, Tang Y, He FY, Yang YT. Application of TQSM polypharmacokinetics and its similarity approach to ascertain Q-marker by analyses of transitivity in vivo of five candidates in Buyanghuanwu injection. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2018; 45:18-25. [PMID: 29555366 DOI: 10.1016/j.phymed.2018.03.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2017] [Revised: 01/05/2018] [Accepted: 03/07/2018] [Indexed: 06/08/2023]
Abstract
BACKGROUND It is well-known that the public still have been facing on a severe issue about the inconsistency of quality and therapeutic efficacy of traditional medicines. Recently, Professor Chang-Xiao Liu has created a new promising concept for identifying relevant quality-markers (Q-marker) from herbs, their formulas and manufacturing products. Therefore, building up a new approach is necessary for us to bridge over quality to efficacy of pharmaceutical products. STUDY DESIGN In this paper, five candidate Q-markers, astragaloside IV, paeonflorin, amygdalin, tetramethylpyrazine, ferulic acid in Buyanghuanwu injection (BYHWI) had been designed to carry out in rat by using single and polypharmacokinetic models for total quanta to ascertain adequate Q-marker. METHODS The Q-marker transitivity in vivo was studied with polypharmacokinetic model and its similarity approach, which were modeled with TQSM principle. The Q-marker was ascertained with transitive similarity and bioavailability in polypharmacokinetics. Their concentrations in plasma sample of white rat were determined by RP-HPLC. Data analyses were used by the DAS software for singles and myself-written-program with EXCEL for multiples. RESULTS In BYHWI, five candidate Q-marker pharmacokinetic profiles were singly fixed to two compartmental models in rat using classical compartmental analysis, but there were tremendous differences among which the candidate parameters were fluctuated from nearly 3552 folds to equivalency. The theoretical value of TQSM polypharmacokinetic parameters such as AUCT, MRTT, VRTT, CLT, VT over the mixure of five drugs were 110.8 ± 51.91 mg min ml-1, 176.0 ± 36.5 min, 39,921 ± 4311 min2, 0.3116 ± 0.02347 ml min-1 kg-1, 54.83 ± 7.683 ml kg-1 respectively. The TQSM polypharmacokinetic parameters in astragaloside Ⅳ ordered by AUCT, MRTT, VRTT, CLT, VT were 110.8 ± 51.91 mg min ml-1, 176.0 ± 36.5 min, 39,921 ± 4311 min2, 0.3116 ± 0.02347 ml min-1 kg-1, 54.83 ± 7.683 ml kg-1, respectively, which were closed to the theoretical values. TQSM similarity versus astragaloside Ⅳ was 0.9661. CONCLUSION The results represented that the optimum Q-marker in BYHWI is astragaloside Ⅳ, whose transitivity in vivo similarity was close to the behavior of polypharmacokinetics with maximum bioavailability to the total quanta. It is feasible for Q-marker in CMMs to screen on the comparison of single pharmacokinetic behavior and bioavailability to the total quanta.
Collapse
Affiliation(s)
- Yu-Tian Zhang
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China
| | - Mei-Feng Xiao
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China; Department of Supramolecular Mechanism and Mathematic-Physics Characterization for Chinese Materia Medicine, Changsha, Hunan 410208, P.R. China
| | - Qiong Liao
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China
| | - Wen-Long Liu
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China; Department of Supramolecular Mechanism and Mathematic-Physics Characterization for Chinese Materia Medicine, Changsha, Hunan 410208, P.R. China
| | - Kai-Wen Deng
- Department of Acupuncture, The First Affinitied Hospital, Hunan University of Tradition Chinese Medicine, Changsha, Hunan 410208, P.R. China; Department of Supramolecular Mechanism and Mathematic-Physics Characterization for Chinese Materia Medicine, Changsha, Hunan 410208, P.R. China
| | - Yi-Qun Zhou
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China; Department of Supramolecular Mechanism and Mathematic-Physics Characterization for Chinese Materia Medicine, Changsha, Hunan 410208, P.R. China
| | - Yu Tang
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China
| | - Fu-Yuan He
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China; Department of Supramolecular Mechanism and Mathematic-Physics Characterization for Chinese Materia Medicine, Changsha, Hunan 410208, P.R. China.
| | - Yan-Tao Yang
- Department of Pharmaceutics, Pharmacy College, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China; Hunan Key Laboratory of Druggability and Preparation Modification for Traditional Chinese Medicine, Changsha, Hunan 410208, P.R. China.
| |
Collapse
|
5
|
Hu S, Cao S, Liu J. Role of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion-induced injury in H9c2 cardiomyocytes. Exp Ther Med 2017; 14:771-779. [PMID: 28672998 PMCID: PMC5488700 DOI: 10.3892/etm.2017.4564] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 02/10/2017] [Indexed: 11/25/2022] Open
Abstract
Fibroblast growth factor 21 (FGF21) exerts a protective effect in ischemia/reperfusion (I/R)-induced cardiac injury. However, the exact molecular mechanism underlying the FGF21 action remains unclear. The present study aimed to evaluate the role of angiopoietin-2 (Angpt2) in the cardioprotective effect of FGF21. For this purpose, the H9C2 cell line was subjected to simulated I/R or aerobic conditions with or without FGF21 administration. Certain groups were also transfected with Angpt2 small interfering RNA (siRNA). Cell viability, apoptosis rate and cell migration were examined, and the expression levels of Angpt2, glucose transporter 1 (GLUT1) and caspase-3 were measured by quantitative polymerase chain reaction (qPCR) and western blot analyses. The results demonstrated that FGF21 administration suppressed apoptosis and increased the cell migration ability following I/R-induced injury. qPCR and western blot data showed a decreased level of GLUT1 after I/R-induced injury, which was reversed by FGF21 administration. Furthermore, inhibition of Angpt2 expression using siRNA enhanced the cardioprotective effect of FGF21 by upregulation of GLUT1. In conclusion, FGF21 administration protected against I/R-induced injury in cardiomyocytes, and further inhibition of Angpt2 with FGF21 administration induced the expression of GLUT1, which may promote the energy metabolism in cardiomyocytes, consequently resulting in a more efficient cardioprotective effect. These results suggested that FGF21 administration and inhibition of Angpt2 could be a novel therapeutic approach for I/R-induced cardiac injury.
Collapse
Affiliation(s)
- Shuoqiang Hu
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China
| | - Shujun Cao
- Department of Cardiology, Beijing Daxing Hospital, Capital Medical University, Beijing 102600, P.R. China
| | - Jinghua Liu
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China
| |
Collapse
|
6
|
He T, Liu X, Li Y, Liu XY, Wu QY, Liu ML, Yuan H. High-dose calcium channel blocker (CCB) monotherapy vs combination therapy of standard-dose CCBs and angiotensin receptor blockers for hypertension: a meta-analysis. J Hum Hypertens 2016; 31:79-88. [PMID: 27511478 DOI: 10.1038/jhh.2016.46] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 05/05/2016] [Accepted: 05/31/2016] [Indexed: 11/09/2022]
Abstract
In this study, we evaluated the efficacy and safety of high-dose calcium channel blocker (CCB) monotherapy and standard-dose CCBs combined with angiotensin receptor blockers (ARBs) for patients with hypertension. A comprehensive search of PubMed, Embase and the Cochrane Central Register of Controlled Trials was performed in December 2015. Randomized controlled trials designed to identify the above goal were included. Thirteen trials including 2371 patients were identified. The standard-dose CCB/ARB combination resulted in a greater reduction of systolic blood pressure (WMD -2.52, 95% confidence interval (CI): -3.76 to -1.28) and diastolic blood pressure (weighted mean difference (WMD) -2.07, 95% CI: -3.73 to -0.42) compared to high-dose CCB monotherapy. The overall hypertension control rate for the CCB/ARB combination was higher than that for CCB monotherapy (relative risk (RR): 1.17, 95% CI: 1.08-1.26). Furthermore, the CCB/ARB combination treatment yielded significantly fewer overall adverse events (RR: 0.84, 95% CI: 0.74-0.95), oedema (RR: 0.31; 95% CI: 0.18-0.52) and rash (RR: 0.27, 95% CI: 0.08-0.96, P=0.04) than did CCB monotherapy. The standard-dose CCB/ARB combination is superior to high-dose CCB monotherapy for lowering blood pressure and reducing adverse events in hypertensive patients. Future research should focus on the cost-effectiveness and long-term effects of these two treatment strategies for patients with hypertension.
Collapse
Affiliation(s)
- T He
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - X Liu
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Y Li
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - X Y Liu
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - Q Y Wu
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| | - M L Liu
- Department of Gerontology, The First Hospital of Beijing University, Beijing, People's Republic of China
| | - H Yuan
- Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.,Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China
| |
Collapse
|